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Abstract
Background:  Urinary tract infections (UTI) are one of the major causes of prescribing and antibiotic con-
sumption. In order to use the best antibiotic treatment for their patients, reliable and recent data about
epidemiology and antibiotic resistance profile of uropathogenic bacteria must be available for clinicians.
Therefore regular monitoring in each country is required.
Objectives:  The aims of this study were to investigate the bacterial pathogenic diversity and antimicrobial
resistance rates of uropathogenic bacteria at the Treichville Teaching Hospital (Abidjan, Ivory Coast) over
a 12-year period (2000–2011) and also to contribute to the monitoring and the geographical adaptation of
antibiotic therapy.
ospective analysis of 12,175 urine samples over a 12-year period 2000–2011
al was carried out according to the routine protocol of urinalysis. The results
rofile prevalence of UTI, the rate of bacterial resistance to antibiotics, the
me and the rate of multidrug resistance.Materials  and  methods:  A retr
at Treichville Teaching Hospit
were processed to obtain the p
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Results:  The presence of bacteria was detected in about 25% of samples in which 3071 bacterial germs
belonging to 12 species were identified. Escherichia  coli  was the dominant species (28.7%) but much
lower than observed in European countries (70–80%). Other main detected species were Staphylococcus
aureus (17.4%), Klebsiella  pneumoniae  (14.9%) and Enterobacter  aerogenes  (10%). These genera were
responsible of 71% of the UTI.
Resistance tests to antibiotics indicated very high rates of resistance to amoxicillin (78.9%), tetracyclin
(76.4%), and trimethoprim/sulfamethoxazole (77.9%). Only a few molecules maintain their effectiveness
such as cefotaxime and netilmicin which respectively exhibit 13.9% and 3.1% of bacterial resistance.
However bacterial resistance is increasing over a time for all antibiotics except chloramphenicol.
Conclusions: The diversity of uropathogenic bacteria obtained appeared to be a characteristic of sub-
Saharan African countries. Their resistances to different antibiotics were following a dramatic trend. Waiting
to be confronted with therapeutic dead end with the advent of multi-resistant bacteria, identifying the
region-specific causes is crucial to adapt antibiotic therapy.
© 2014 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. 
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Open access under CC BY-NC-ND license.Introduction
Urinary tract infections (UTI) are one of the major reasons for
antibiotic prescribing [1]. Among the uropathogenic bacteria,
Escherichia coli  is predominant in both community and nosoco-
mial UTI. However, the diversity of uropathogens is known to
vary regionally [2]. Infections are gradually becoming more and
more difficult to treat and may lead to therapeutic dead ends.
These resistance patterns have shown large inter-regional variabil-
ity.
Understanding the spectrum and resisitance patterns may help guide
effective empirical antibiotic therapies, decrease treatment failure
and costs. [3]. In most countries, several structures such as con-
ferences of consensus on the proper use of antibiotics and drug
commissions in Teaching Hospitals draw on knowledge of the ser-
vices microbial ecology to define a reasoned use of antibiotics.
Empiric antibiotic therapy is usually based on epidemiological
data which are updated and adapted geographically, highlighting
the importance of local and regular monitoring of bacterial resis-
tance.
Although bacterial resistance to antibiotics is specific to each
region, but no country can protect itself from the import
of resistant pathogens through travel and trade [4]. The aim
of this study was to assess the diversity and state of resis-
tance of uropathogenic bacteria to antibiotics. Data were
collected for a 12-year long period (2000–2011) at the Cen-
tral Laboratory of Treichville Teaching Hospital (Abidjan, Ivory
Coast).
Subjects and  methods
Samples
During the study period, 12,175 urine samples from outpatients and
inpatients were collected in different health services and analyzed.
Under sterile condition, the midstream urine sample was collected
on the first morning urine or on urination performed four hours later.
These samples were quickly recorded and processed according to
the routine protocol of urinalysis.
c
g
(
oamples  processing
icroscopic examination of urine (0.1 mL) was performed to
numerate sample, leukocytes, erythrocytes, urothelial cells and
rystals. The results helped to make the initial diagnosis of a possi-
le urinary tract infection. Samples (5 mL) exhibiting more than 104
eukocytes per mL were centrifuged (5000 ×g  for 20 min at 4 ◦C)
nd pellets were stained with coomassie blue. These results were
sed to orientate the choice of isolation medium.
rine sample (0.01 mL) was inoculated on CLED agar (Cystine-
actose-Electrolyte-Deficient), which allows the growth of most
ropathogenic bacteria. More selective isolation media were also
sed according to the results of the qualitative direct test. Enterobac-
eriaceae selection was made on Drigalski agar, MacConkey agar or
MB (Eosin Methylene Blue) agar. The Gram-positive cocci were
elected on blood agar supplemented with colistin. The isolated
acteria were then identified by their biochemical characteristics
sing API galleries.
ntimicrobial  susceptibility  testing
ntibiotic susceptibility was determined using the disc diffusion
ethod on Mueller Hinton agar according to the guidelines of the
ntibiogram Committee of the “Société Franc¸aise de Microbiolo-
ie” (CA-SFM) [5].
ifferent families of antibiotics (discs obtained from Diag-
ostic Pasteur) were studied such as: cephems (cefuroxime,
efotaxime, ceftazidime, ceftriaxone); penicillins (amoxicillin,
iperacillin; beta-lactam + inhibitor: amoxicillin/clavulanic acid);
onobactam (aztreonam); quinolones (norfloxacin, ofloxacin,
efloxacin, nalidixic acid); aminoglycosids (gentamicin, netilmicin,
obramycin); tetracyclins (minocyclin, tetracyclin); trimetho-
rim/sulfamethoxazole; fosfomycin; lipopeptide (polymyxin B);
hloramphenicol. After incubation, the diameter of the inhibition
one formed around the disc was measured and compared to the
ritical values “d” and “D” of each antibiotic disc to qualify the tar-
et bacteria as sensitive (diameter of the inhibition > D) or resistant
diameter of the inhibition < d) or again intermediate (d  < diameter
f the inhibition < D). Control tests were performed with reference
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Table  1  Profile prevalence of uropathogenic bacteria isolated.
Bacteria isolated Total number (%) From inpatients (%) From outpatients (%)
Acinetobacter sp. 176 (5.7%) 80 (6.5%) 96 (5.3%)
Enterobacter aerogenes 307 (10.0%) 136 (11.0%) 171 (9.3%)
Enterobacter cloacae 124 (4.1%) 47 (3.8%) 77 (4.2%)
Enterobacter sp. 83 (2.7%) 37 (3.0%) 46 (2.5%)
Escherichia coli 879 (28.7%) 345 (28.0%) 534 (29.2%)
Klebsiella oxytoca 248 (8.1%) 87 (7.1%) 161 (8.8%)
Klebsiella pneumoniae 456 (14.9%) 221 (17.9%) 235 (12.8%)
Proteus mirabilis 80 (2.6%) 50 (4.1%) 30 (1.6%)
Pseudomonas aeruginosa 163 (5.3%) 75 (6.1%) 88 (4.8%)
Salmonella sp. 12 (0.4%) 6 (0.5%) 6 (0.3%)
Salmonella Typhi 2 (0.1%) 0 (0.0%) 2 (0.1%)
Staphylococcus aureus 534 (17.4%) 150 (12.2%) 384 (21.0%)
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ATotal 3064 (100%) 
trains E.  coli  ATCC 25922, Staphylococcus  aureus  ATCC 25923
nd Pseudomonas  aeruginosa  ATCC 27853.
ata processing  and  statistical  analysis
ata were analyzed with WHONET 5.6 software provided by the
orld Health Organization [2,6] to characterize and quantify the
pidemiology of urinary tract infections. The percentage of antibi-
tic resistance, their evolution over time and the rates of multi
esistant strains isolated were also assessed. Multi Resistant strains
ere divided into MDR (Multiple Drug-Resistant), XDR (Exten-
ively Drug-Resistant) and PDR (Pandrug-resistant) according to
he European Center for Disease prevention and Control [7]. MDR
acteria are defined as resistant to at least three different classes of
ntibiotics. XDR bacteria are characterized by their sensitivity to
nly one class of antibiotics and the PDR bacteria are resistant to
ll classes of antibiotics recommended for treatment.
omparison between the rate of antibiotic resistance in strains from
npatients and outpatients was performed by chi-square (ξ2). The
ochran–Armitage test was used to study the trends of antibiotic
esistance over time. These statistical tests were performed using
LSTAT software 2009 version and the threshold for statistical
ignificance was p  < 0.05.
esults
pidemiology  of  urinary  tract  infections
f 12,175 urine samples processed, 3058 samples exhibited evi-
ence of infection. Bacterial pathogens isolated (3071) belong to
2 species. E.  coli  (28.7%) was the commonest pathogen isolated
ith S.  aureus  (17.4%), Klebsiella  pneumoniae  (14.9%) and Entero-
acter aerogenes  (10%) (Table 1). These genera represent 71% of
solated bacterial strains. A majority of them were isolated from
utpatients (59.6%)
ntibiotic resistance
omparison of antibiotic resistance rates was performed specif-
cally for E.  coli  and for all strains combined (Table 2). Very
igh rates of resistance to amoxicillin, tetracycline and trimetho-
rim/sulfamethoxazole were observed (close to 80%). Other
ntibiotics maintained their relative activity, such as ceftazidime,
T
r
p4 (100%) 1830 (100%)
obramycin, cefotaxime, aztreonan, polymyxin and especially
etilmicin (3%). These results were observed both for E.  coli
nd for all strains combined whatever they came from in- or
utpatients. However antibiotic effectiveness declines over time
Fig. 1). The bacterial resistance rates to amoxicillin and cefo-
axime dramatically increase respectively of 25% and 54.2% from
000 to 2010 to reach close to 100%. Although the average
ate of chloramphenicol resistance over 12 years was high, a
ecrease of 32.6% was observed from 2002 to 2010. E.  coli
nd all strains combined exhibit similar trends of antibiotic resis-
ance.
ulti-resistant strains
ased on their phenotypes, multi-resistant strains were classified by
HONET 5.6 software as MDR, possible XDR or possible PDR
Table 3). Most bacterial species presented a multiple drug resis-
ance higher than 20%, particularly for P.  aeruginosa  (36.2%) and
nterobacter sp. (35.5%). The chi-square test showed that the rates
f MDR and XDR strains from inpatients were significantly higher
han those of outpatients (Fig. 2).
iscussion
iversity of  uropathogens
e compared the diversity of uropathogens isolated at Treichville
eaching Hospital (Abidjan, Ivory Coast) from 2000 to 2011 to that
eported in similar studies from worldwide regions. As expected,
. coli  was shown to be the commonest infecting uropathogen. How-
ver, we reported a lower prevalence of E.  coli  infection (less than
0%) as compared to European studies (over 60%) [8]. S.  aureus
nd K.  pneumoniae  accounted for a higher fraction of isolates in our
tudy than reported in European studies (less than 1%). Such results
re similar to those reported from studies in sub-Saharan Africa
9–15] (Fig. 3). This specificity of uropathogenic bacteria diversity
ay be due by climatic factors, life conditions and habits of local
opulation.
ntimicrobial resistancehe antimicrobial resistance profile of isolates in our study
evealed a generally higher resistance rate than reported in Euro-
ean studies. Penicillins studied exhibited a resistance rate higher
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Table  2  Number and resistance rates for different antibiotics.
Antibiotic subclass Antibiotic All strains combined Escherichia coli
Inpatients Outpatients ξ2 test Inpatients Outpatients ξ2 test
Nb %R Nb %R p-Value Nb %R Nb %R p-Value
Penicillins Amoxicillin 328 78.9 574 75.7 0.276 92 84.7 164 85.3 0.810
Piperacillin 178 38.7 247 26.7 0.009 53 47.1 80 26.2 0.013
Amox/Cl. acid 480 48.7 541 43.4 0.089 151 41.7 161 34.1 0.169
Cephalosporin II Cefuroxime 715 37.9 918 29.1 <0.001 222 22.0 320 18.1 0.256
Cephalosporin
III
Cefotaxime 410 13.9 567 14.8 0.688 135 6.6 222 12.1 0.095
Ceftazidime 694 15.5 889 13.5 0.246 240 8.7 350 10.8 0.402
Ceftriaxone 100 21.0 187 11.7 0.037 43 16.2 91 8.7 0.199
Monobactam Aztreonam 186 12.9 191 14.1 0.726 65 7.6 62 8.0 0.938
Fluoroquinolones Norfloxacin 156 28.2 164 26.2 0.690 45 24.4 37 27.0 0.790
Ofloxacin 137 27.7 260 20.0 0.080 37 24.3 65 21.5 0.746
Pefloxacin 165 25.4 251 16.3 0.023 44 36.3 58 15.5 0.015
Quinolones Nalidixic acid 199 48.7 210 35.7 0.008 64 42.1 65 33.8 0.329
Aminoglycosides Gentamicine 227 17.1 422 9.0 0.002 69 17.3 153 7.1 0.021
Netilmicin 811 3.0 1121 4.1 0.203 248 1.2 327 2.1 0.398
Tobramycin 99 15.1 117 10.2 0.278 28 17.86 24 12.5 0.593
Tetracyclines Minocycline 188 56.3 280 47.8 0.070 59 52.5 78 50.0 0.768
Tetracycline 82 73.1 85 76.4 0.623 26 73.1 24 75.0 0.095
Folate pathway inhibitors Trim./Sulf. 314 81.8 395 77.9 0.203 93 84.9 114 78.9 0.268
Fosfomycin Fosfomycin 75 10.6 166 18.0 0.144 24 4.1 48 6.2 0.716
Polymyxin Polymyxin B 216 12.0 207 12.5 0.870 76 6.5 101 8.9 0.569
Phenicole Chloramphenicol 276 55.8 488 44.6 0.003 85 49.4 150 41.3 0.231
Note: Nb: number; %R: resistance rate.
p values in bold are considered as significant.
hran–
ed.
tFigure  1  Trends in antibiotic resistance from 2000 to 2011 with Coc
Note: Filled circles: Escherichia  coli, open triangles: all strains combin
than cephalosporins, especially those of the third generation. We
observed that resistance rates of E.  coli  from UTI to amoxicillin were
the highest (85%). Such a strong resistance was observed worldwide
[8,15–17]. This rate rose from 67% in 2000 to 91% in 2010. With
E. coli  strains, the rate of resistance increased from 62.5% in 2000
(
T
tArmitage test.
o 88.6% in 2010. Similar trend had also been observed in Dakar
Senegal) [17].
he combination of amoxicillin/clavulanic acid was more active
han amoxicillin alone, but the observed resistance remained high
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Table  3  Percentage of multidrug resistance for each identified species.
Isolates Total number MDR (%) XDR (%) PDR (%)
Escherichia coli 879 127 (14.38%) 80 (9.06%) 11 (1.25%)
Staphylococcus aureus 534 32 (5.98%) 21 (3.93%) 8 (1.50%)
Klebsiella pneumoniae 456 106 (23.14%) 71 (15.50%) 14 (3.06%)
Enterobacter aerogenes 307 62 (20.20%) 45 (14.66%) 9 (2.93%)
Klebsiella oxytoca 248 61 (24.60%) 41 (16.53%) 11 (4.44%)
Acinetobacter sp. 176 59 (33.52%) 40 (22.73%) 15 (8.52%)
Pseudomonas aeruginosa 163 59 (36.20%) 48 (29.45%) 5 (3.07%)
Enterobacter cloacae 124 44 (35.48%) 33 (26.61%) 4 (3.23%)
Enterobacter sp. 83 30 (36.14%) 28 (33.73%) 0 (0.00%)
Proteus mirabilis 80 16 (20.00%) 10 (12.50%) 1 (1.25%)
Salmonella sp. 12 3 (25.00%) 3 (25.00%) 0 (0.00%)
Salmonella Typhi 2 0 (0.00%) 0 (0.00%) 0 (0.00%)
Total 3064 599 (19.51%) 420 (13.68%) 78 (2.54%)
Figure  2  Comparing of the rates of multidrug resistant from outpatients versus those from inpatients with chi-square test.
Note: Filled rectangles: multiresistant from inpatients, empty rectangles: multiresistant from outpatients. NS: non significant.
F
Nigure  3  Regional specificity of prevalence of two uropathogenic bacteria
ote: Filled rectangles: European countries, empty rectangles: sub-Saharan A (E.  coli  and S.  aureus).
frican countries.
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in Ivory Coast (34%). This value was lower than that observed in
some African countries [15,17,18].
Third generation cephalosporins retained their relative efficiency.
More than 80% of isolates were sensitive to ceftriaxone, ceftazidime
and cefotaxime. Cephalosporin efficiency was lower than those
observed in some countries in Africa and Europa [16,19]. These
cephalosporins had retained some activity on uropathogenic bacte-
ria in Ivory Coast and Africa, but the trend tests revealed that their
efficiency was decreasing gradually over time. The rate of resistance
to ceftazidime increased significantly from 3% in 2000 to 50% in
2008 (p-value < 0.0001). Resistance to cefotaxime evolved from 9%
in 2000 to 39% in 2009 (p  < 0.0001).
There was also a positive trend for the rate of resistance of E.  coli  to
cefuroxime, a second-generation cephalosporin. This value evolved
from 17% in 2000 to 54% in 2008 (p-value = 0.0004).
About the family of quinolones, the resistance rate of E.  coli  to
nalidixic acid, to norfloxacin and to ofloxacin were less than those
encountered in some African and European countries [10,20,21].
In the family of aminoglycosides, our results had shown a low rate of
resistance of E.  coli  to gentamicin from outpatients (7%) as observed
in Africa and in Europa [16,17,19,20]. We recorded a high rate of
resistance to this antibiotic in some African countries such as Nigeria
and Morocco [10,13,15]. The most recent one (netilmicin) appeared
to be the most effective. The average rate of E.  coli  resistance during
these 12 years was 2.14%. However the trend test performed had
indicated a growth of the rate of resistance to this antibiotic (p-
value = 0.02).
Chloramphenicol was used less often because of its toxicity. The
average resistance to this antibiotic in Ivory Coast between 2000
and 2011 was 41% and has been decreasing over years. This resis-
tance rate was lower than that observed in Nigeria in 2008–2009
(52%)[13].
Multi-drug resistant
In agreement with the consensus conference jointly organized by the
French Infectious Diseases Society (SPILF) and the French Asso-
ciation of Urology (AFU), we had observed significantly higher
percentage of MDR and possible XDR bacteria strains from inpa-
tients than those of outpatients [22]. The uropathogens bacteria
genus of Acinetobacter  and Enterobacter  were exhibiting the high-
est rates of MDR strain.
Conclusion
Our study had given an overview of the common uropathogens
bacteria found in Ivory Coast and had shown a specific bacte-
rial diversity in African countries compared to that of European
countries. The spectrum of antibiotics activities showed that some
antibiotics retain their efficiency on urinary tract infections such
as third-generation cephalosporins, aminoglycosides, monobac-
tams, lipopeptides and fosfomycin. The antimicrobial resistance
increase overtime whatever their effectiveness. Moreover, high
level of MDR and the emergence of XDR and PDR strains were
observed.
[an 23
n Ivory Coast as well as in other developing countries, some habits
ere already identified as actions which promote the emergence
f resistant bacterial strains to antibiotics such as self-medication,
upported by the sale of illegal drugs [23].
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